Old Web
English
Sign In
Acemap
>
authorDetail
>
Ioannis Pyrousis
Ioannis Pyrousis
University of Patras
Medicine
non-small cell lung cancer (NSCLC)
Immunology
Pathology
immune checkpoint inhibitors
4
Papers
6
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19
2021
Arezina N. Kasti
Kalliopi D. Synodinou
Ioannis Pyrousis
Maroulla D. Nikolaki
Konstantinos D. Triantafyllou
Show All
Source
Cite
Save
Citations (0)
Intensive nutrition support may benefit patients with a rare mitochondrial disorder.
2021
Nutrition in Clinical Practice
Arezina Kasti
Maroulla Nikolaki
Ioannis Pyrousis
Kalliopi Synodinou
Nikolaos Oikonomopoulos
Konstantinos Triantafyllou
Show All
Source
Cite
Save
Citations (0)
PIOS ratio: predicting the best response of non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors.
2020
Journal of Clinical Oncology
Foteinos-Ioannis D. Dimitrakopoulos
Achilleas Nikolakopoulos
Anastasia E. Kottorou
Elias Liolis
Theodora Frantzi
Ioannis Pyrousis
Foteini Kalofonou
Angelos Koutras
Thomas Makatsoris
Haralabos P. Kalofonos
Show All
Source
Cite
Save
Citations (1)
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.
2020
Cancers
Foteinos-Ioannis D. Dimitrakopoulos
Achilleas Nikolakopoulos
Anastasia E. Kottorou
Fotini Kalofonou
Elias Liolis
Theodora Frantzi
Ioannis Pyrousis
Angelos Koutras
Thomas Makatsoris
Haralabos P. Kalofonos
Show All
Source
Cite
Save
Citations (5)
1